Synopsis
Determine whether an environmental mycobacterial isolate represents pulmonary, disseminated, device-related or cutaneous disease; exclude tuberculosis first; and select a species- and susceptibility-led multidrug plan with the monitoring needed for prolonged toxic therapy.
- An acid-fast smear is not a species result. Use M tuberculosis molecular testing and culture before relaxing infection control or applying an NTM label.
- For pulmonary disease, combine symptoms, characteristic CT and reproducible microbiology; one low-burden sputum isolate can be contamination or transient carriage.
- Two separate sputum cultures growing the same species strengthen pulmonary causality; one positive bronchoscopic sample or compatible biopsy can satisfy the microbiological component in the right syndrome.
- Species and subspecies change both pathogenicity and treatment: MAC, M kansasii, M xenopi, M malmoense and M abscessus cannot share one generic regimen.
- NTM can also cause disseminated MAC in advanced HIV, catheter or surgical-site infection, skin and soft-tissue disease after procedures, and M marinum infection after aquatic exposure.
- Do not give macrolide monotherapy for active MAC disease or before excluding NTM in someone considered for long-term bronchiectasis macrolide prophylaxis; resistance can remove the pivotal drug.
- Stable non-cavitary pulmonary disease may be observed with defined culture, symptom and imaging triggers, whereas smear positivity, cavities, systemic illness or objective progression favours treatment.
- Pulmonary MAC therapy usually continues for at least 12 months after culture conversion; disseminated MAC duration also depends on clinical response, ART success and immune recovery.
- Routine person-to-person spread is unusual, but cystic-fibrosis services use additional cross-infection policies and healthcare-associated clusters may require infection-prevention investigation.
Key red flags
Upper-lobe cavities, pleural thickening, haemoptysis and weight loss resemble tuberculosis or chronic fungal disease and usually justify faster specialist assessment.
Persistent fever, night sweats, weight loss, anaemia or pancytopenia, lymphadenopathy, hepatosplenomegaly and raised alkaline phosphatase suggest bloodstream and reticuloendothelial infection.
Indolent draining nodules, wound inflammation, catheter infection or postoperative collections after injection, surgery or cosmetic procedure may yield M abscessus, M chelonae or M fortuitum complex.
Investigation priorities
Demonstrate reproducible pulmonary isolation and quantify organism burden before treatment.
Management branches
A respiratory smear or culture reports acid-fast mycobacteria before species is known.
- Review TB epidemiology, symptoms and imaging and maintain the local airborne pathway when pulmonary TB remains plausible.
- Request rapid M tuberculosis complex testing and retain cultures for definitive species and susceptibility rather than assuming the smear is TB or NTM.
- Communicate the provisional uncertainty to the patient and infection-prevention team and assign ownership of every pending result.